Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Asset Allocation median (36 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 07 Mar 2024 – 20 Aug 2026, limited by Quantum Multi Asset Allocation Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Quantum Multi Asset Allocation Fund | Nifty 50 |
|---|---|---|
| 07 Mar 2024 | ₹100.00 | ₹100.00 |
| 21 May 2024 | ₹102.60 | ₹100.16 |
| 03 Aug 2024 | ₹107.00 | ₹109.89 |
| 17 Oct 2024 | ₹109.30 | ₹110.03 |
| 31 Dec 2024 | ₹107.70 | ₹105.12 |
| 15 Mar 2025 | ₹106.70 | ₹99.57 |
| 29 May 2025 | ₹114.80 | ₹110.40 |
| 12 Aug 2025 | ₹113.60 | ₹108.86 |
| 25 Oct 2025 | ₹119.70 | ₹114.68 |
| 08 Jan 2026 | ₹121.80 | ₹115.04 |
| 24 Mar 2026 | ₹114.10 | ₹101.86 |
| 06 Jun 2026 | ₹116.70 | ₹103.88 |
| 20 Aug 2026 | ₹120.10 | ₹107.73 |
| Metric | Quantum · Regular NAV ₹12.01 High risk ★★☆☆☆ 1Y | Category median Multi Asset Allocation · 36 funds |
|---|---|---|
| +4.53% | +13.66% | |
| — | +15.55% | |
| — | +13.48% | |
| — | +11.02% | |
| +7.75% | +12.56% | |
| +5.55% | — | |
| — | +14.34% | |
| — | +11.77% | |
| — | +10.03% | |
| Risk | ||
| 7.67% | 10.32% | |
| -0.26 | 0.81 | |
| -0.35 | 1.11 | |
| -10.72% | -12.33% | |
| Nifty 50 | — | |
| — | +7.29% | |
| — | 0.62 | |
| — | 83.8% | |
| — | 24.4% | |
| 2.02% | 2.15% | |
| ₹56.95Cr | ₹2,048Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 2% | 53% | |
| Sneha Pandey | — | |
| 07 Mar 2024 | — | |
| 40 | — | |
| 27.5% | — | |
| 2.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.